BioArctic announces start of Phase 1 study of ABBV-0805 for Parkinson’s disease

BioArctic announces start of Phase 1 study of ABBV-0805 for Parkinson’s disease

Publication date: Mar 14, 2019

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the first clinical study with ABBV-0805 has started in the U. S. AbbVie is responsible for the clinical development of ABBV-0805.

ABBV-0805 is a result of a strategic research alliance between BioArctic and AbbVie focused on the development of a potential immunotherapy for Parkinson’s disease.

Concepts Keywords
AbbVie AbbVie Inc.
Antibodies Parkinson
Antibody Companies
CEO Alpha
Clinical Trial Antibodies
Immunotherapy Immunotherapy
Nasdaq Stockholm
Parkinson
Tolerability

Semantics

Type Source Name
drug DRUGBANK Nonoxynol-9
disease MESH development
pathway BSID Release

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *